Skip to main navigation menu Skip to main content Skip to site footer

Viewpoint

Vol. 147 No. 4748 (2017)

HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies?

DOI
https://doi.org/10.4414/smw.2017.14559
Cite this as:
Swiss Med Wkly. 2017;147:w14559
Published
20.11.2017

References

  1. Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, et al.; RIS HPV TT study group. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014;27(12):1559–67. doi:.https://doi.org/10.1038/modpathol.2014.55
  2. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282–8. doi:.https://doi.org/10.1002/cncy.21544
  3. Zhao C, Li Z, Nayar R, Levi AW, Winkler BA, Moriarty AT, et al. Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012: results of a retrospective multicenter study. Arch Pathol Lab Med. 2015;139(2):184–8. doi:.https://doi.org/10.5858/arpa.2014-0028-OA
  4. Zhao C, Yang H, Li Z. Cytopathology and more: evidence emerging for HPV-negative cervical cancer [serial online]. CAP Today. Available at http://www.captodayonline.com/cytopathology-and-more-evidence-emerging-for-hpv-negative-cervical-cancer/. Accessed February 10, 2017.
  5. Genotypen des humanen Papillomavirus in Krebs-vorstufen und Krebserkrankungen am Gebärmutterhals in der Schweiz zu Beginn der kantonalen Impfprogramme: die CIN3+plus Studie BAG-Bulletin 2017; Nr 6:12-18 available from: For the German version: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/infektionskrankheiten/hpv/hpv-cin3plusplus-studie.pdf.download.pdf/hpv-cin3plusplus-studie-de.pdf. For the French version: https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/infektionskrankheiten/hpv/hpv-cin3plusplus-studie.pdf.download.pdf/hpv-cin3plusplus-studie-fr.pdf
  6. Available from. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003852/human_med_001863.jsp&mid=WC0b01ac058001d124
  7. Available from. http://www.nordicehealth.se/hpvcenter/
  8. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al.; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32. doi:.https://doi.org/10.1016/S0140-6736(13)62218-7
  9. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97. doi:.https://doi.org/10.1056/NEJMoa073204
  10. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88. doi:.https://doi.org/10.1016/S1470-2045(11)70296-0
  11. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672–82. doi:.https://doi.org/10.1016/S1470-2045(09)70156-1
  12. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al., New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57. doi:.https://doi.org/10.1016/S1470-2045(09)70360-2
  13. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al.; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32. doi:.https://doi.org/10.1016/S0140-6736(13)62218-7
  14. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8):dju153. doi:.https://doi.org/10.1093/jnci/dju153
  15. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97. doi:.https://doi.org/10.1016/j.ygyno.2014.11.076
  16. Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Available from www.thelancet.com/public-health, Vol 2 February 2017.
  17. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:.https://doi.org/10.1016/S1470-2045(10)70230-8
  18. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2011;13(4):377–81. doi:.https://doi.org/10.1016/j.jmoldx.2011.03.007
  19. Lagheden C, Eklund C, Kleppe SN, Unger ER, Dillner J, Sundström K. Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. J Clin Virol. 2016;80:36–9. doi:.https://doi.org/10.1016/j.jcv.2016.04.016
  20. Rodríguez-Carunchio L, Soveral I, Steenbergen RDM, Torné A, Martinez S, Fusté P, et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG. 2015;122(1):119–27. doi:.https://doi.org/10.1111/1471-0528.13071
  21. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20. doi:.https://doi.org/10.1002/ijc.24010
  22. Petry KU, Cox JT, Johnson K, Quint W, Ridder R, Sideri M, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer. 2016;138(12):2932–9. doi:.https://doi.org/10.1002/ijc.30032
  23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9. doi:.https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  24. Böhmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol. 2003;189(1):118–20. doi:.https://doi.org/10.1067/mob.2003.439
  25. Liebrich C, Brummer O, Von Wasielewski R, Wegener G, Meijer C, Iftner T, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol. 2009;30(1):45–8.
  26. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35. doi:.https://doi.org/10.1002/ijc.25396
  27. Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas De Souza S, et al. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer. 2015;137(12):2858–68. doi:.https://doi.org/10.1002/ijc.29651
  28. Kurman RJ, Carcangiu ML, Herrington CS, et al., eds. WHO classification of tumors of female reproductive organs, 4th edn., vol. 6. Geneva: World Health Organization, 2014
  29. Hopenhayn C, Christian A, Christian WJ, Watson M, Unger ER, Lynch CF, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014;18(2):182–9. doi:.https://doi.org/10.1097/LGT.0b013e3182a577c7
  30. Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, et al.; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011;128(6):1344–53. doi:.https://doi.org/10.1002/ijc.25723
  31. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–71. doi:.https://doi.org/10.1016/j.ejca.2011.01.008
  32. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. Vaccine. 2012;30(Suppl.5):F88–99. doi:.. Erratum in: Vaccine. 2013;52:6266..https://doi.org/10.1016/j.vaccine.2012.06.095
  33. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer. 2012;106(5):975–81. doi:.https://doi.org/10.1038/bjc.2011.581
  34. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al.; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5, Suppl 1):S1–27. doi:.https://doi.org/10.1097/LGT.0b013e318287d329
  35. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88–99. doi:.https://doi.org/10.1093/jnci/djn444

Most read articles by the same author(s)

1 2 > >>